See more : Vodafone Group Public Limited Company (VOD) Income Statement Analysis – Financial Results
Complete financial analysis of Lexaria Bioscience Corp. (LEXX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Lexaria Bioscience Corp., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Embracer Group AB (publ) (THQQF) Income Statement Analysis – Financial Results
- I.C.P. Israel Citrus Plantations Ltd. (CTPL5.TA) Income Statement Analysis – Financial Results
- Sumitomo Corporation (8053.T) Income Statement Analysis – Financial Results
- Kginicis Co.,Ltd (035600.KQ) Income Statement Analysis – Financial Results
- Stockwik Förvaltning AB (publ) (STWK.ST) Income Statement Analysis – Financial Results
Lexaria Bioscience Corp. (LEXX)
About Lexaria Bioscience Corp.
Lexaria Bioscience Corp. operates as a biotechnology company. Its patented drug delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients enter the bloodstream by promoting effective oral delivery. The company's DehydraTECH has demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and in some instances with cannabinoids by 27x compared to standard industry formulations, reduce time of onset from 1 - 2 hours to minutes, and mask unwanted tastes; and is also being evaluated for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (NSAIDs), PDE5 inhibitors, and others. DehydraTECH also deliver drugs effectively across the blood brain barrier. It operates a licensed in-house research laboratory and holds intellectual property portfolio with 23 patents granted and approximately 50 patents pending worldwide. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 464.28K | 226.21K | 255.40K | 722.74K | 384.54K | 222.61K | 433.29K | 63.64K | 40.72K | 14.70K | 1.10M | 1.36M | 1.13M | 362.47K | 421.96K | 900.79K | 253.15K | 20.31K | 20.31K |
| Cost of Revenue | 4.82K | 31.50K | 71.84K | 175.35K | 99.38K | 22.89K | 25.19K | 29.75K | 45.62K | 29.88K | 795.20K | 783.27K | 667.86K | 273.62K | 548.32K | 912.75K | 124.91K | 93.32K | 93.32K |
| Gross Profit | 459.46K | 194.71K | 183.56K | 547.39K | 285.17K | 199.72K | 408.10K | 33.89K | -4.90K | -15.18K | 302.25K | 574.49K | 465.91K | 88.86K | -126.37K | -11.96K | 128.24K | -73.01K | -73.01K |
| Gross Profit Ratio | 98.96% | 86.07% | 71.87% | 75.74% | 74.16% | 89.72% | 94.19% | 53.25% | -12.03% | -103.26% | 27.54% | 42.31% | 41.09% | 24.51% | -29.95% | -1.33% | 50.66% | -359.55% | -359.55% |
| Research & Development | 2.36M | 3.67M | 1.84M | 1.26M | 387.07K | 555.73K | 492.86K | 54.19K | 9.02K | 146.47K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 3.85M | 3.06M | 5.72M | 4.97M | 3.57M | 3.13M | 6.02M | 1.63M | 1.01M | 1.49M | 1.27M | 561.89K | 678.09K | 466.67K | 458.04K | 475.34K | 1.01M | 121.44K | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 204.28K | 515.36K | 489.06K | 209.03K | 185.46K | 276.56K | 8.19K | 3.47K | 40.92K | 559.00 | 930.00 | 4.11K | 20.07K | 20.07K | 0.00 |
| SG&A | 3.85M | 3.06M | 5.72M | 4.97M | 3.77M | 3.64M | 6.51M | 1.84M | 1.20M | 1.76M | 8.19K | 565.35K | 719.01K | 467.23K | 458.97K | 479.45K | 1.03M | 141.51K | 35.14K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 112.75K | 60.55K | 2.31K | -886.00 | 4.60K | -22.66K | 0.00 | 14.04K | 6.40K | 0.00 | 8.21K | 1.28K | 148.38K | -2.99K | 0.00 |
| Operating Expenses | 6.21M | 6.73M | 7.57M | 6.23M | 4.27M | 4.26M | 7.01M | 1.90M | 1.21M | 1.91M | 8.19K | 579.40K | 725.41K | 474.00K | 467.18K | 480.72K | 1.18M | 138.53K | 35.14K |
| Cost & Expenses | 6.22M | 6.76M | 7.64M | 6.41M | 4.37M | 4.28M | 7.03M | 1.92M | 1.26M | 1.94M | 803.40K | 1.36M | 1.39M | 747.61K | 1.02M | 1.39M | 1.30M | 231.85K | 35.14K |
| Interest Income | 14.31K | 43.19K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 94.00 | 4.09K | 18.09K | 6.12K | 6.12K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.02K | 2.25K | 31.54K | 267.36K | 246.61K | 278.73K | 167.32K | 160.12K | 857.58K | 4.71K | 21.91K | 21.91K |
| Depreciation & Amortization | 76.15K | 145.40K | 146.91K | 147.60K | 146.09K | 60.55K | 2.31K | 1.49K | 619.00 | -22.66K | 1.52M | 456.60K | 370.62K | 122.16K | 342.13K | 453.12K | 148.38K | 81.76K | 40.44K |
| EBITDA | -5.68M | -6.39M | -6.52M | -5.58M | -4.00M | -4.10M | -6.61M | -1.92M | -1.26M | -1.95M | 294.06K | -35.30K | 442.73K | 111.12K | -236.15K | -244.37K | -414.37K | -891.03K | -129.78K |
| EBITDA Ratio | -1,222.75% | -2,824.23% | -2,835.72% | -977.11% | -982.78% | -1,752.23% | -1,522.76% | -2,922.37% | -2,983.84% | -13,269.46% | 26.79% | 33.27% | 9.80% | -72.55% | -59.58% | 37.67% | -356.22% | 730.49% | 26.11% |
| Operating Income | -5.75M | -6.53M | -7.38M | -5.69M | -3.89M | -3.96M | -6.60M | -1.86M | -1.22M | -1.93M | 294.06K | -4.90K | -259.50K | -552.46K | -753.67K | -898.09K | -1.05M | -489.66K | -35.14K |
| Operating Income Ratio | -1,239.16% | -2,888.50% | -2,891.05% | -786.85% | -1,012.10% | -1,779.43% | -1,523.29% | -2,924.71% | -2,985.36% | -13,115.30% | 26.79% | -0.36% | -22.89% | -152.42% | -178.61% | -99.70% | -414.83% | -2,411.28% | -173.02% |
| Total Other Income/Expenses | -55.52K | -178.50K | -764.61K | 1.52M | 0.00 | -228.06K | -8.97K | -6.02K | -34.70K | -55.06K | -355.23K | -246.61K | -276.22K | -278.73K | 0.00 | 7.05K | -73.27K | -565.19K | -473.12K |
| Income Before Tax | -5.81M | -6.71M | -7.38M | -4.16M | -4.08M | -4.16M | -6.61M | -1.93M | -1.28M | -1.98M | -1.87M | -251.51K | -538.23K | -552.46K | -753.67K | -971.35K | -1.05M | -211.54K | -75.58K |
| Income Before Tax Ratio | -1,251.12% | -2,967.41% | -2,891.05% | -576.16% | -1,062.20% | -1,868.03% | -1,525.36% | -3,031.89% | -3,136.82% | -13,489.80% | -170.50% | -18.52% | -47.47% | -152.42% | -178.61% | -107.83% | -416.69% | -1,041.70% | -372.16% |
| Income Tax Expense | 0.00 | 0.00 | -114.33K | -1.66M | -54.29K | 39.62K | -8.97K | -54.17K | -60.23K | -181.23K | 294.06K | 246.61K | 278.73K | 167.32K | -94.00 | 7.14K | 1.04K | 574.84K | 40.59K |
| Net Income | -5.80M | -6.66M | -7.27M | -2.50M | -4.03M | -4.20M | -6.60M | -1.87M | -1.21M | -1.77M | -1.87M | -251.51K | -538.23K | -552.46K | -753.57K | -978.49K | -1.06M | -508.26K | -75.72K |
| Net Income Ratio | -1,248.25% | -2,946.36% | -2,846.28% | -346.50% | -1,048.08% | -1,885.83% | -1,522.97% | -2,937.31% | -2,983.38% | -12,042.58% | -170.50% | -18.52% | -47.47% | -152.42% | -178.59% | -108.63% | -417.10% | -2,502.87% | -372.89% |
| EPS | -0.47 | -1.01 | -1.24 | -0.57 | -1.45 | -1.62 | -2.79 | -0.95 | -0.83 | -1.34 | -0.07 | -0.42 | -1.09 | -1.22 | -2.80 | -4.46 | -5.21 | -3.16 | -1.37 |
| EPS Diluted | -0.47 | -1.01 | -1.24 | -0.57 | -1.45 | -1.62 | -2.79 | -0.95 | -0.83 | -1.34 | -0.07 | -0.42 | -1.09 | -1.22 | -2.80 | -4.46 | -5.21 | -3.16 | -1.37 |
| Weighted Avg Shares Out | 12.38M | 6.61M | 5.89M | 4.39M | 2.77M | 2.59M | 2.37M | 1.96M | 1.46M | 1.32M | 25.71M | 602.48K | 493.23K | 451.94K | 268.67K | 219.28K | 202.59K | 160.87K | 55.15K |
| Weighted Avg Shares Out (Dil) | 12.38M | 6.61M | 5.89M | 4.39M | 2.77M | 2.59M | 2.37M | 1.96M | 1.46M | 1.32M | 25.71M | 602.48K | 493.23K | 451.94K | 268.67K | 219.28K | 202.59K | 160.87K | 55.15K |
Lexaria Announces Closing of $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
KELOWNA, BC / ACCESSWIRE / February 16, 2024 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq;LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced that it has closed its previously announced registered direct offering priced at-the-market under Nasdaq...
Lexaria Announces $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
KELOWNA, BC / ACCESSWIRE / February 15, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced that it has entered into definitive agreements for the purchase and sale of 1,558,443...
Lexaria's Submits Investigational New Drug Application
KELOWNA, BC / ACCESSWIRE / January 30, 2024 / Lexaria Bioscience Corp. (Nasdaq:LEXX; LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that, on January 29, it submitted its much-anticipated Investigational New Drug ("IND") application with...
Lexaria Releases Annual Letter from the CEO
KELOWNA, BC / ACCESSWIRE / January 24, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX),(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to provide this annual letter from CEO Chris Bunka as a strategic update to...
Lexaria Unveils Extensive Planned 2024 GLP-1 Study Program
Extensive work program designed to support commercial discussions. KELOWNA, BC / ACCESSWIRE / January 16, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX) & (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces a comprehensive planned applied research...
Lexaria Bioscience Corp. (NASDAQ: LEXX) Proprietary Drug-Delivery System Improves Way Molecules Enter Bloodstream
NEW YORK, Jan. 11, 2024 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) announces the availability of a broadcast titled, “Exciting New Cures Possible from GLP-1 Diabetes, Weight-Loss Drugs.”
Lexaria Bioscience Corp. (NASDAQ: LEXX) Improves Delivery, Efficacy of GLP-1 Agonists Through Proprietary Drug-Delivery Platform
NEW YORK, Jan. 09, 2024 (GLOBE NEWSWIRE) -- via InvestorWire — Lexaria Bioscience Corp. (NASDAQ: LEXX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 60+ brands within the Dynamic Brand Portfolio @ IBN ( InvestorBrandNetwork ),...
Lexaria's Patented Technology Improved the Oral Performance of the Rybelsus(R)-Branded GLP-1 drug Semaglutide
Final results from a human pilot study show DehydraTECHTM-powered semaglutide outperforms Rybelsus®: Sustained higher levels of semaglutide in blood; Better blood glucose control; Faster achievement of peak drug delivery; and Reduced side effects. KELONA, BC / ACCESSWIRE / January 4,...
Lexaria's Investigational New Drug Application Filing Update
KELOWNA, BC / ACCESSWIRE / December 7, 2023 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that the Company's anticipated submission of an Investigational New Drug ("IND") application with the U.S....
Lexaria's Technology Lowers Blood Glucose More Effectively than Rybelsus(R)-Branded GLP-1 drug Semaglutide Alone in Human Pilot Study
DehydraTECHTM-powered semaglutide achieved these benefits in a human pilot study compared to Rybelsus ® : Sustained lower levels of blood glucose from baseline including nearly 10x lower after 24 hours; Lower blood-glucose spike after eating; and Successful first-ever DehydraTECH test...
Source: https://incomestatements.info
Category: Stock Reports